An investigation on 4-thiazolidinone derivatives as dual inhibitors of aldose reductase and protein tyrosine phosphatase 1B, in the search for potential agents for the treatment of type 2 diabetes mellitus and its complications
作者:Rosanna Maccari、Antonella Del Corso、Paolo Paoli、Ilenia Adornato、Giulia Lori、Francesco Balestri、Mario Cappiello、Alexandra Naß、Gerhard Wolber、Rosaria Ottanà
DOI:10.1016/j.bmcl.2018.10.024
日期:2018.12
considered a promising alternative to combinations of drugs, when monotherapy results to be unsatisfactory. In this work, compounds 1–17 were synthesized and in vitro evaluated as DMLs directed to aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two key enzymes involved in different events which are critical for the onset and progression of type 2 DM and related pathologies. Out of the
当单药治疗效果不理想时,设计出的多种配体(DMLs)被开发为可同时调节参与多种因素的多种病因,例如糖尿病(DM)的发病机制的选定靶标,被认为是药物组合的一种有前途的替代方法。在这项工作中,化合物1 - 17合成和体外评价涉及醛糖还原酶(AR)和蛋白酪氨酸磷酸酶1B(PTP1B)的DML,参与其是2型的发病和进展的关键不同事件的两个关键酶糖尿病和相关病理。在测试的4-噻唑烷酮衍生物中,化合物12和16表现出强力的AR抑制作用以及对PTP1B的有趣抑制作用,可被认为是进一步优化和平衡双重抑制作用的先导化合物。此外,几个结构部分被确定为可用于通过结合两种靶酶的非催化区域同时抑制人AR和PTP1B的特征。